Mr Lamberto Andreotti, CEO, Bristol-Myers Squibb
The quarter was highlighted by strong performance by key brands, significant data and regulatory milestones for Opdivo, the launch of the company's hepatitis-C regimens in Japan and Europe and the completion of several business development transactions supporting the company's oncology portfolio.
"Our financial results in the third quarter reflect our continued focus on balancing long-term growth with short-term performance, as we achieved significant progress in our pipeline and saw strong in-market performance for key products including Eliquis, Yervoy, Sprycel and Orencia," said Mr Lamberto Andreotti, CEO, Bristol-Myers Squibb. "We continue to build a solid foundation for our future as a Diversified Specialty BioPharma by advancing our own R&D efforts and investing in strategic business development to build a sustainable pipeline."
THIRD QUARTER FINANCIAL RESULTS
• Bristol-Myers Squibb posted third quarter 2014 revenues of $3.9 billion, a decrease of 4 percent compared to the same period a year ago. Excluding the divested Diabetes Alliance, global revenues increased 7 percent.
• US revenues decreased 3 percent to $2.0 billion in the quarter compared to the same period a year ago. International revenues decreased 4 percent.